Patents by Inventor Jeffrey O'Meara

Jeffrey O'Meara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8198458
    Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Patrick DeRoy, Anne-Marie Faucher, Alexandre Gagnon, Serge R. Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
  • Publication number: 20120077737
    Abstract: Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1a R155K, genotype 1b D168V and genotype 1a D168V resistance mutations. The compounds of the invention are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
    Type: Application
    Filed: November 23, 2010
    Publication date: March 29, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Montse Llinas-Brunet, Josée Bordeleau, Cédrickx Godbout, Mélissa Leblanc, Benoît Moreau, Jeffrey O'Meara
  • Publication number: 20110294778
    Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, maintain good activity against NS3 proteases containing clinically relevant genotype 1a R155K and genotype 1b D168V resistance mutations. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
    Type: Application
    Filed: November 23, 2010
    Publication date: December 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Montse LLINAS-BRUNET, Josée BORDELEAU, Cédrickx GODBOUT, Mélissa LEBLANC, Benoît MOREAU, Jeffrey O'MEARA
  • Patent number: 7807670
    Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: October 5, 2010
    Assignee: Boehringer Ingelheim Canada Ltd.
    Inventors: Christiane Yoakim, Bruno Hache, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
  • Publication number: 20100087382
    Abstract: Compounds of formula I: wherein R1, R2, R2a, R3, R4 and R5 are defined herein, are useful as inhibitors of the HCV NS3 protease.
    Type: Application
    Filed: February 15, 2008
    Publication date: April 8, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Murray D. Bailey, Francois Bilodeau, Pasquale Forgione, Vida Gorys, Montse Llinas-Brunet, Julie Naud, Jeffrey O'Meara, Marc-Andre Poupart
  • Publication number: 20100041649
    Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A, X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.
    Type: Application
    Filed: November 13, 2008
    Publication date: February 18, 2010
    Inventors: Christiane Yoakim, Bruno Hache, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
  • Patent number: 7642277
    Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: January 5, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
  • Patent number: 7569723
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: August 4, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
  • Publication number: 20090143370
    Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.
    Type: Application
    Filed: February 3, 2009
    Publication date: June 4, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patrick DeROY, Anne-Marie FAUCHER, Alexandre GAGNON, Serge LANDRY, Sebastien MORIN, Jeffrey O'MEARA, Bruno SIMONEAU, Bounkham THAVONEKHAM, Christiane YOAKIM
  • Patent number: 7528167
    Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A, X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: May 5, 2009
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Christiane Yoakim, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
  • Patent number: 7517998
    Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 14, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
  • Publication number: 20080114068
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.
    Type: Application
    Filed: January 15, 2008
    Publication date: May 15, 2008
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
  • Patent number: 7300948
    Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table R1 R2 R4 R5 R8a F CF3 Me H —OH F CF3 Cl H —OH F CF3 Me H —O—CH2CO2H Cl CN Cl H —OH.
    Type: Grant
    Filed: September 29, 2005
    Date of Patent: November 27, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O′Meara, Bruno Simoneau, Christiane Yoakim
  • Patent number: 7273861
    Abstract: Compounds represented by formula 1: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or methyl; R3 is H or (C1-4)alkyl; R4 is H or (C1-4)alkyl; R5 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cyclo-alkyl or (C3-7)cycloalkyl; and W is a fused phenyl-5 or 6-membered heterocycle having one or two heteroatoms selected from N or S; or W is phenyl, 1,1?-biphenyl, 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthyl, or naphthyl; said W being optionally substituted with (C1-4)alkyl, which in turn can be optionally substituted with a carboxy or (C1-4)alkoxycarbonyl, or a salt or ester thereof. The compounds have inhibitory activity against Wild Type, single and double mutant strains of HIV.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: September 25, 2007
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Christiane Yoakim, Jeffrey O'Meara, Bruno Simoneau, William Ogilvie, Robert Déziel
  • Publication number: 20060235010
    Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A, X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.
    Type: Application
    Filed: May 12, 2006
    Publication date: October 19, 2006
    Applicant: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Christiane Yoakim, William Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
  • Patent number: 7119099
    Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: October 10, 2006
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Christiane Yoakim, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
  • Publication number: 20060069261
    Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table.
    Type: Application
    Filed: September 29, 2005
    Publication date: March 30, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O'Meara, Bruno Simoneau, Christiane Yoakim
  • Publication number: 20060025480
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.
    Type: Application
    Filed: July 19, 2005
    Publication date: February 2, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
  • Publication number: 20050282907
    Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.
    Type: Application
    Filed: May 24, 2005
    Publication date: December 22, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
  • Publication number: 20050054639
    Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.
    Type: Application
    Filed: November 21, 2003
    Publication date: March 10, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim